- TRADE NAME: Zelboraf (Roche)
- INDICATIONS: Melanoma (metastatic or unresectable)
- CLASS: BRAF inhibitor
- HALF-LIFE: 57 hours
- CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:
Amoxapine, Arsenic, Atazanavir, Carbamazepine, Clarithromycin, CYP substrates, Dolasetron, Efavirenz, Indinavir, Itraconazole, Ketoconazole, Nefazodone, Nelfinavir, Pazopanib, Phenobarbital, Phenytoin, Rifabutin, Rifampin, Rifapentine, Ritonavir, Saquinavir, Telavancin, Telithromycin, Voriconazole, Warfarin
Please login to view the rest of this drug profile.
DRUG REVIEW ARTICLE
Click on the DRUG REVIEW ARTICLE tab (above) to see a review of vemurafenib in the Taylor & Francis journal Expert Opinion on Drug Safety.
(Note that non-subscribers to the journal will only be able to see an abstract of the article.)
Page last updated 02/01/2024